Literature DB >> 25089597

Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT.

X-Y Qin1, G-X Li1, Y-Z Qin1, Y Wang1, F-R Wang1, D-H Liu1, L-P Xu1, H Chen1, W Han1, J-Z Wang1, X-H Zhang1, J-L Li1, L-D Li1, K-Y Liu1, X-J Huang2.   

Abstract

This study evaluates the prognostic significance of quantitative chimerism to monitor minimal residual disease and predict relapse in acute leukemia (AL) patients following allogeneic hematopoietic SCT (HSCT). The quantitative chimerism levels of 129 AL patients were measured using RQ-PCR based on 29 sequence polymorphisms. Receiver-operating characteristic curve indicated that the optimal cutoff point to predict an inevitable relapse was 1.0%, which results in 100.0% sensitivity and 79.6% specificity.The relapse rate of patients with chimerism >1.0% at 2 years was 55.0%, whereas that for patients with chimerism <1.0% was 0%(P=0.000). Quantitative chimerism >1.00% indicated a higher probability of relapse. Cox multivariate analysis indicated that quantitative chimerism >1.00% was associated with lower disease-free survival (hazard ratio (HR)=10.825; 95% confidence interval (CI) =4.704-24.912, P=0.000) and lower OS (HR=8.681; 95% CI=3.728-20.212, P=0.000). Patients (24/47 with quantitative chimerism >1.00%) who received preemptive modified DLI immunotherapy had significantly lower relapse rate (37.5%) than those (n=9) who did not (100%; P=0.001). Thus, quantitative chimerism is an independent prognostic factor that predicts clinical outcomes after HSCT and provides a guide for suitable interventions.

Entities:  

Mesh：

Year:  2014        PMID： 25089597     DOI： 10.1038/bmt.2014.158

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  54 in total

1.  Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.

Authors:  Eva Rettinger; Andre M Willasch; Hermann Kreyenberg; Arndt Borkhardt; Wolfgang Holter; Bernhard Kremens; Brigitte Strahm; Wilhelm Woessmann; Christine Mauz-Koerholz; Bernd Gruhn; Stefan Burdach; Michael H Albert; Paul-Gerhardt Schlegel; Thomas Klingebiel; Peter Bader
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

2.  Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial.

Authors:  F Locatelli; M Zecca; R Rondelli; F Bonetti; G Dini; A Prete; C Messina; C Uderzo; M Ripaldi; F Porta; G Giorgiani; E Giraldi; A Pession
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

3.  Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse.

Authors:  O Horky; J Mayer; L Kablaskova; F Razga; M Krejci; J Kissova; M Borsky; I Jeziskova; D Dvorakova
Journal:  Int J Lab Hematol       Date:  2011-02       Impact factor: 2.877

4.  Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases.

Authors:  F Frassoni; A J Barrett; A Grañena; P Ernst; G Garthon; H J Kolb; H G Prentice; J P Vernant; F E Zwaan; A Gratwohl
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

5.  Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.

Authors:  X-J Huang; D-H Liu; K-Y Liu; L-P Xu; H Chen; W Han; Y-H Chen; J-Z Wang; Z-Y Gao; Y-C Zhang; Q Jiang; H-X Shi; D-P Lu
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

6.  Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia.

Authors:  X-J Huang; D-H Liu; L-P Xu; H Chen; W Han; K-Y Liu; D-P Lu
Journal:  Leukemia       Date:  2006-02       Impact factor: 11.528

7.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

8.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.

Authors:  John E Levine; Thomas Braun; Samuel L Penza; Patrick Beatty; Kenneth Cornetta; Rodrigo Martino; William R Drobyski; A John Barrett; David L Porter; Sergio Giralt; Jose Leis; Houston E Holmes; Matthew Johnson; Mary Horowitz; Robert H Collins
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

9.  Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.

Authors:  P Bader; T Klingebiel; A Schaudt; U Theurer-Mainka; R Handgretinger; P Lang; D Niethammer; J F Beck
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

10.  Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies.

Authors:  B Horn; S Soni; S Khan; A Petrovic; N Breslin; M Cowan; G Pelle-Day; E Cooperstein; L-A Baxter-Lowe
Journal:  Bone Marrow Transplant       Date:  2008-10-27       Impact factor: 5.483
View more
  16 in total

1.  Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation.

Authors:  Anne Bouvier; Jérémie Riou; Sylvain Thépot; Aurélien Sutra Del Galy; Sylvie François; Aline Schmidt; Corentin Orvain; Marie-Hélène Estienne; Alban Villate; Damien Luque Paz; Laurane Cottin; Bénédicte Ribourtout; Annaëlle Beucher; Yves Delneste; Norbert Ifrah; Valérie Ugo; Mathilde Hunault-Berger; Odile Blanchet
Journal:  Leukemia       Date:  2019-11-25       Impact factor: 11.528

2.  Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

Authors:  E Yokohata; Y Kuwatsuka; H Ohashi; S Terakura; N Kawashima; A Seto; S Kurahashi; Y Ozawa; T Goto; N Imahashi; T Nishida; K Miyao; R Sakemura; T Kato; M Sawa; A Kohno; H Sao; H Iida; H Kiyoi; T Naoe; K Miyamura; M Murata
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

Review 3.  A practical guide to chimerism analysis: Review of the literature and testing practices worldwide.

Authors:  Amanda G Blouin; Fei Ye; Jenifer Williams; Medhat Askar
Journal:  Hum Immunol       Date:  2021-08-14       Impact factor: 2.211

4.  Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiang-Yu Zhao; Xing-Xing Yu; Zheng-Li Xu; Xun-Hong Cao; Ming-Rui Huo; Xiao-Su Zhao; Ying-Jun Chang; Yu Wang; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Blood Adv       Date:  2019-12-23

5.  Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.

Authors:  Thomas Pincez; Raoul Santiago; Michel Duval; Sonia Cellot; Henrique Bittencourt; Isabelle Louis; Mélanie Bilodeau; Alexandre Rouette; Loubna Jouan; Josette-Renée Landry; Françoise Couture; Johanne Richer; Pierre Teira
Journal:  Bone Marrow Transplant       Date:  2021-09-02       Impact factor: 5.483

6.  Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation.

Authors:  Xiaosu Zhao; Xiangyu Zhao; Mingrui Huo; Qiaozhen Fan; Xuying Pei; Yu Wang; Xiaohui Zhang; Lanping Xu; Xiaojun Huang; Kaiyan Liu; Yingjun Chang
Journal:  J Immunol Res       Date:  2017-04-16       Impact factor: 4.818

7.  Impact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation.

Authors:  Monika Lejman; Agnieszka Zaucha-Prażmo; Joanna Zawitkowska; Aleksandra Mroczkowska; Dominik Grabowski; Jerzy R Kowalczyk; Katarzyna Drabko
Journal:  BMC Cancer       Date:  2019-11-26       Impact factor: 4.430

8.  CTLA-4 polymorphisms and haplotype correlate with survival in ALL after allogeneic stem cell transplantation from related HLA-haplotype-mismatched donor.

Authors:  X-Y Qin; Y Wang; G-X Li; Y-Z Qin; F-R Wang; L-P Xu; H Chen; W Han; J-Z Wang; X-H Zhang; Y-J Chang; K-Y Liu; Z-F Jiang; X-J Huang
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

9.  Systematic comparison of donor chimerism in peripheral blood and bone marrow after hematopoietic stem cell transplantation.

Authors:  C Bach; M Steffen; W Roesler; J Winkler; A Mackensen; K-D Stachel; M Metzler; B M Spriewald
Journal:  Blood Cancer J       Date:  2017-06-02       Impact factor: 11.037

Review 10.  Current Trends in Applications of Circulatory Microchimerism Detection in Transplantation.

Authors:  Hajnalka Andrikovics; Zoltán Őrfi; Nóra Meggyesi; András Bors; Lívia Varga; Petra Kövy; Zsófia Vilimszky; Fanni Kolics; László Gopcsa; Péter Reményi; Attila Tordai
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.